Shares of Ocular Therapeutix rose 7% on Nov. 6 after the biopharma reported better-than-expected third quarter results driven by the demand for Dextenza, …
Shares of Ocular Therapeutix rose 2.1% in Wednesday’s extended market trading session after closing 28.
As fears of a tech bubble and stretched valuations become the talk of the town, investors are turning to Wall Street titans for …
When it comes down to it, investors are focused on a single factor: a stock’s ability to deliver returns. As Wall Street observers …
H.C.
Last Friday, Ocular Therapeutix (OCUL) announced that the company had received a warning letter from the FDA. The letter relates to the company’s …
Ocular Therapeutix (OCUL), Catalyst Pharmaceuticals (CPRX) and AcelRx Pharmaceuticals (ACRX) look forward to important regulatory approval decisions this year. Could these catalysts give these small …
JMP analysts have profiled two biopharmaceutical firms that they believe are set up to do well in the rest of 2018 and beyond. Both companies are …
Evercore ISI: Teva throws lawsuit at competitor Lilly; Guggenheim: OCUL’s assets looking at $$$ billions.
Ocular Therapeutix Inc (NASDAQ:OCUL) shares are on a roughly 4% dip today after the biotech firm released second-quarter financial results- a quarter that …
